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Abstract
Background: Retroperitoneal tumors are often massive and can involve adjacent organs and/or vital structures,
making them difficult to resect. Completeness of resection is within the surgeon’s control and critical for long-term
survival, particularly for malignant disease. Few studies directly address strategies for complete and safe resection of
challenging retroperitoneal tumors.
Methods: Fifty-six patients representing 63 cases of primary or recurrent retroperitoneal tumor resection between
2004-2009 were identified and a retrospective chart review was performed. Rates of complete resection, use of
adjunct procedures, and perioperative complications were recorded.
Results: In 95% of cases, complete resection was achieved. Fifty-eight percent of these cases required en bloc
multi-organ resection, and 8% required major vascular resection. Complete resection rates were higher for primary
versus recurrent disease. Adjunct procedures (ureteral stents, femoral nerve monitoring, posterior laminotomy, etc.)
were used in 54% of cases. Major postoperative complications occurred in 16% of cases, and one patient died (2%
mortality).
Conclusions: Complete resection of challenging retroperitoneal tumors is feasible and can be done safely with
important pre- and intraoperative considerations in mind.
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Background
Retroperitoneal tumors are relatively uncommon but
can be very challenging to manage, even for the experi-
enced surgeon. For malignant disease, which accounts
for most retroperitoneal tumors [1,2], prognosis depends
on tumor grade and histologic subtype, completeness of
resection, and presence of distant metastases [3-6].
These factors are for the most part, dependent on
tumor biology; however, the ability to completely resect
a retroperitoneal tumor is within the control of the sur-
geon and has tremendous impact on long-term survival
[3,4,6]. With greater experience and improved operative
technique, many centers have recently reported com-
plete resection rates over 90% and, consequently, better
clinical outcome [7-9]. However, as retroperitoneal
tumors can be enormous and often involve multiple
adjacent organs and vital structures, successful complete
resection must also be carefully balanced with patient
safety.
Few studies directly address strategies for complete
and safe resection of challenging retroperitoneal tumors.
In this retrospective review, we describe important pre-
and intraoperative considerations based on our recent
experience with challenging retroperitoneal tumors in
patients at a tertiary referral center.
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After obtaining institutional review board approval, we
identified 56 adult patients with primary or recurrent
retroperitoneal tumors who underwent a total of 63
resections at the University of California San Francisco
Medical Center between 2004 and 2009. Their charts
were retrospectively reviewed to determine rates of
complete resection and perioperative complications.
Specific attention was also given to adjunct procedures
used to improve resectability and minimize complica-
tions. Data was also collected regarding patient demo-
graphics (age, sex), tumor characteristics (size,
pathology, grade), operative details (blood loss, operative
time) and hospital course (length of stay).
Before surgery, all patients underwent a thorough eva-
luation of co-morbid conditions, and cardiac and pul-
monary function were optimized. Contrast-enhanced
computed tomographic scanning or magnetic resonance
imaging was done to evaluate the local extent of tumor
and rule out presence of metastatic disease before resec-
tion. On the basis of their preoperative imaging results,
patients were further evaluated by consulting services as
needed (e.g., urology for ureteral stent placement and/or
nephrectomy; vascular surgery for major vessel resec-
tion, graft selection/sizing and reconstruction; neurosur-
gery for potential spinal nerve root involvement).
Preoperative tissue diagnosis was available in some
patients but was not required before surgery if the result
would not have affected patient care.
Results
Median age for all patients was 52 years (range 22-77)
with an even distribution of male and female patients.
Out of 63 retroperitoneal tumor resections, 35 (56%)
were performed for primary disease, 28 (44%) for recur-
rence. Median operative time was 316 minutes (range
149-759). Median estimated blood loss was 500 cc
(range 50-25,000).
Complete resection, as defined by macroscopically
negative margins (R0-R1), was achieved in 95% of all
operations performed (Table 1). In three patients, com-
plete resection was not possible because of extensive
peritoneal sarcomatosis at laparotomy (n = 2) and sig-
nificant intraoperative bleeding (n = 1, discussed below).
Complete resection was feasible, but achieved slightly
less often in resections performed for recurrent tumors
(93%) versus primary tumors (97%, Table 1). Tumor
involvement of adjacent organs necessitated concomi-
tant en bloc resection to achieve macroscopically nega-
tive margins in 58% of all cases (Table 1). The kidney,
colon, and pancreas were the most frequently involved
and resected organs. In 8% of cases, major vascular (e.g.
inferior vena cava, iliac vessel) resection was required.
In each case, anatomic vascular reconstruction was done
immediately after resection by using synthetic tube
grafts (for inferior vena cava) or cryopreserved human
vein (for iliac vessels) (Figure 1). Among patients who
had complete resection, the rates of multi-organ or
major vascular resection were higher in those with pri-
mary disease (71%; n = 24/34) than in those with recur-
rent disease (62%; n = 16/26).
Several pre-operative and intraoperative adjunct pro-
cedures were used to facilitate safe and complete resec-
tion in 54% of cases (Table 1). The decision to use any
of these procedures was based on careful review of pre-
operative imaging studies that raised concern for tumor
involvement of critical structures. For example, in three
patients, a posterior laminotomy was done by neurosur-
geons because preoperative imaging suggested spinal
nerve root involvement. In two patients whose CT scans
suggested high tumor vascularity, preoperative angioem-
bolization was done by interventional radiologists to
limit intraoperative blood loss. To help identify and
Table 1 Operative Details
No. of cases (%)
Complete Resection Total Primary Recurrent
(out of n = 63 cases: 35 primary, 28
recurrent)
60
(95)
34 (97) 26 (93)
Multi-organ Resection 35
(58)
21 (62) 14 (54)
(out of n = 60 cases with complete
resection)
Kidney 18
(30)
10 8
Colon 10
(17)
37
Pancreas 4 (7) 3 1
Small bowel 3 (5) 1 2
Adrenal 3 (5) 3 0
Bladder 2 (3) 2 0
Liver 1 (2) 1 0
Spleen 1 (2) 1 0
Diaphragm 1 (2) 1 0
Iliac wing 1 (2) 0 1
Major Vascular resection 5 (8) 3 (9) 2 (8)
(out of n = 60 cases with complete
resection)
IVC 4 (7) 3 1
Iliac artery, vein 1 (2) 0 1
Adjunct Procedures
(out of n = 63 cases)
Posterior laminotomy 3 (5) 2 1
Angioembolization 2 (3) 2 0
Ureteral stent 22
(35)
14 8
Femoral nerve monitoring 7 (11) 3 4
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placed by urologists before laparotomy in 35% of resec-
tions. Intraoperative femoral nerve monitoring, which
we described previously [10], was done in 11% of cases
to help identify the femoral nerve and prevent post-
operative disability when involvement was suspected
based on the location of the tumor and/or symptoms (e.
g. paresthesias, pain, weakness).
With the exception of one patient with significant
intraoperative bleeding (discussed below), all patients
tolerated resection of their retroperitoneal tumor with-
out intraoperative complications. A total of 24 complica-
tions were observed in the postoperative period. When
scored according to the revised Accordion Classification
scheme [11], the majority of complications were mild to
moderate (Grade 1-3, Table 2). Major postoperative
complications, as defined by organ failure, need for reo-
peration, or death (Grade 4-6), occurred in 16% of
cases. The most common complication overall was
intra-abdominal abscess, which was managed by percu-
taneous drainage and parenteral antibiotics in all cases.
The second most common complication was postopera-
tive atrial fibrillation, which occurred in 4 patients. One
patient had pre-existing atrial fibrillation, and none
experienced a myocardial infarction. Atrial fibrillation
was thought to be related to perioperative intravascular
volume shifts and atrial stretch.
One patient had significant intraoperative bleeding
that precluded complete resection and ultimately died
(2% 30-day series mortality). This patient had a primary
epithelioid tumor with invasion into the vagina and rec-
t u mt h a tr e q u i r e dp a r t i a lv a ginectomy and abdomino-
perineal resection. Tumor dissection close to the sacrum
led to profuse venous bleeding and massive blood trans-
fusion requirements that necessitated damage control
measures and cessation of surgery. The patient devel-
oped multi-organ failure and died on postoperative day
four.
In total, median length of hospital stay for all patients
was 7 days (range 4-72). 38% (24/63) required post-
operative recovery in the intensive care unit and among
those patients, median length of stay was 4 days (range
1-23).
The final pathology results of resected retroperitoneal
tumors revealed that 69% of cases had malignant dis-
ease. Among the malignant tumors, retroperitoneal sar-
coma was the most common diagnosis (72%, n = 32/
44). Liposarcoma was the most common sarcoma sub-
type (55%; n = 24/44), followed by leiomyosarcoma
(18%; n = 8/44) (Figure 2a). Rare diagnoses such as
undifferentiated pleomorphic sarcomas and spindle cell
sarcomas were also seen. Among the benign tumors,
schwannomas and paragangliomas were the most fre-
quent (Figure 2b). Tumor sizes ranged from 2 to 48 cm,
with a median of 14 cm. Only four tumors (7%) were
less than 5 cm.
Discussion
Retroperitoneal tumors can be very challenging to man-
age. Large, single institution case series of retroperito-
neal tumors suggest that most are malignant [1,2]. For
malignant disease (i.e., sarcomas), completeness of resec-
tion is a critical prognostic factor for survival [3,4,6]. In
fact, a recently proposed revised staging system and a
survival nomogram both incorporate completeness of
resection [12,13]. However, because retroperitoneal
tumors are often enormous and close to critical
IVC
a b
c d
Figure 1 Retroperitoneal Tumor Involvement of the Inferior
Vena Cava (IVC). Preoperative computed tomography scan
demonstrates IVC involvement without obvious venous
collateralization (a). The tumor was resected en bloc with a portion
of the IVC (b) and reconstructed using synthetic
polytetrafluoroethylene (PTFE) tube graft (c). Follow-up imaging was
done postoperatively (d).
Table 2 Complications
Revised Accordion Classification [ref [10]]
Grade Type/Intervention Needed No. of
cases
1 Minor procedures done at bedside 2
2 Pharmacologic treatment, blood transfusions,
TPN
12
3 Endoscopic or interventional procedure 6
4 General anesthesia, single organ failure 3
5 Multi-organ (>2) organ failure 0
6 Death 1
Total 24
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tion is difficult and the potential for perioperative com-
plications is high. The results of our study suggest that
for most patients, complete and safe resection is possi-
ble, but multi-organ and major vascular resections are
frequently required and several adjunct procedures may
be utilized to minimize complications.
For retroperitoneal tumors, large case series indicate
that multi-organ resection is to be anticipated in up to
80% of patients, with the kidney being the most com-
mon organ resected en bloc with the primary tumor
[3,4,6]. Although preoperative imaging studies may sug-
gest adjacent organ involvement, often, definitive assess-
ment can only be made intraoperatively. This
underscores the importance of preoperative planning,
especially if the visceral organs to be resected are out-
side of the surgeon’s area of technical expertise. Assis-
tance from consulting services may be needed.
Recently, Bonvalot et al. have advocated “complete
compartmental surgery”, which involves multi-organ
resection, even without obvious tumor involvement of
adjacent organs at the time of surgical exploration [14].
In a retrospective review of 382 patients undergoing ret-
roperitoneal sarcoma resection, the authors found that
this technique was associated with a 3-fold decrease in
local recurrence in comparison to standard multi-organ
resection only for tumor involvement. However, no dif-
ference in survival was noted. Santos et al. found that
the technique of compartmental surgery did not appear
to impact either recurrence rates or survival and was in
fact, associated with higher intraoperative blood transfu-
sion requirements and postoperative morbidity [15]. We
did not utilize complete compartmental surgery in our
series and believe that more studies are needed to vali-
date its routine use.
Retroperitoneal tumors can also involve major abdom-
inal vascular structures in up to 18% of patients [16],
necessitating concomitant en bloc resection, as was
done in five (8%) of our cases. Preoperative planning is
critical and should include consultation with a vascular
surgeon for resection and reconstruction. For right-
sided tumors, the surgeon must be prepared to resect
Liposarcoma (55%) Other (15%)
MPNST 
(12%)
Leiomyosarcoma (18%)
a
Desmoid (11%)
Myelipoma
(11%)
Lipoma
(11%)
Paraganglioma (11%) Schwannoma (22%)
Other (34%)
b
Figure 2 Final Pathology of Retroperitoneal Tumors. Among malignant tumors (a), sarcoma was the most common diagnosis. A variety of
pathology was encountered for benign tumors (b). MPNST = malignant peripheral nerve sheath tumor.
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Most published reports in patients with non-hepatic,
non-renal primary retroperitoneal tumors advocate use
of synthetic graft (e.g. polytetrafluoroethylene, PTFE) to
reconstruct the IVC [16-19]. Graft patency rates are
very good (90-94%), as shown by studies with 19 to 36
months of follow-up review [16-19]. Alternatively, proxi-
mal ligation of the IVC after resection may be appropri-
ate in select patients whose infrarenal tumors have
extensive venous collateralization, or when concern for
bowel anastomotic leakage would make synthetic graft
placement risky. Minimal morbidity was reported in 11
patients who had proximal IVC ligation [20], but a sub-
sequent report found that postoperative leg edema was
t w i c ea sc o m m o na f t e rI V Cl i g a t i o nt h a na f t e rg r a f t
reconstruction [21]. Finally, although more rare and
arguably more challenging, aortic resection for retroperi-
toneal tumors has also been described [16,22,23]. A vari-
ety of graft materials have been used for aortic resection,
including Dacron [16], PTFE [16,22], polyethylene ter-
ephthalate [22], and even autologous superficial femoral
vein [23]. Five patients with aortic resection and pros-
thetic reconstruction were reported to have a patency
rate of 89% at 19 months [16]. For both venous and
arterial reconstruction, the option of using cryopre-
served human vein or extra-anatomic bypass (i.e. axil-
lary-femoral) also exist, particularly when there is
concern for enteric contamination within the resection
site. In select cases, extracorporeal circulatory bypass
may be helpful to permit complete and safe resection of
retroperitoneal tumors with major vascular involvement
[24].
In our series, complete resection was feasible for recur-
rent retroperitoneal tumors, although it was achieved
slightly less often than for primary tumors (93% versus
97%, Table 1). Even more dramatic differences were
reported by Lewis et al. more than a decade ago - 80% of
patients with primary disease had complete resection ver-
sus 57% for those with local recurrence, and not surpris-
ingly, the rate of complete resection continued to
decrease with each subsequent recurrence [3]. Similar to
our findings, more recent studies indicate a difference in
the rate of complete resection, but suggest that the differ-
ence may not be as dramatic (99% versus 90%) [9]. The
recent higher rates of complete resection for recurrent
disease may reflect improved surgical technique, a more
aggressive approach to resection of all retroperitoneal
tumors, or improved patient selection. Complete resec-
tion should always be considered for recurrent disease as
it is critical for improved survival [25] and in fact, may
even result in comparable survival to patients after com-
plete resection of primary disease [26].
Careful review of preoperative imaging is essential to
anticipate potential operative scenarios and determine
whether to utilize adjunct procedures to minimize com-
plications. For example, ureteral stent placement and
femoral nerve monitoring should be considered to iden-
tify these important structures when masses are near to
their expected location in the retroperitoneum. Posterior
laminotomy should be considered to permit complete
resection of retroperitoneal tumors involving spinal
nerve roots and when masses abut the vertebral bodies.
Preoperative angioembolization of highly vascular
tumors should be considered to minimize intraoperative
blood loss.
Despite use of adjunct procedures, perioperative com-
plications are common given the magnitude of the
operations often required in retroperitoneal tumor
resection. In terms of perioperative mortality, our 2%
rate compares favorably to the 1-3% rates reported for
large single institution patient cohorts [3,6] and a recent
ACS-NSQIP national database review [27]. Our compli-
cation rate of 16% is also comparable to the recent 13-
26% rates reported in the literature [6,27]. The caveat of
reporting complications, of course, is that they are heav-
ily dependent on the experience and expertise of the
surgeon(s) and the resources of the institution, and are
to some extent, driven by extent of the operation, which
may differ from one patient to another.
Although not performed in our current series, laparo-
scopic resection of retroperitoneal tumors is emerging
as a potential surgical option in select cases. Two recent
series have suggested that in benign tumors without
adjacent organ or vessel involvement, this approach can
be done safely and result in good perioperative out-
comes [28,29]. Tumor size does not appear to signifi-
cantly affect blood loss or operative time, although the
majority of tumors are relatively small (<10 cm).
Laparoscopic resection of retroperitoneal liposarcoma
[30,31] and leiomyosarcoma [32,33] have also been
described in case reports. We feel that use of this
approach in malignant disease should be tempered by
the same oncologic principles of complete and safe
resection and that there should be a low threshold for
conversion to laparotomy in cases of actual or potential
adjacent organ involvement.
Conclusion
Our recent series of sixty-three cases of challenging pri-
mary and recurrent retroperitoneal tumor resections
indicates that complete resection is feasible and can be
done safely. The surgeon must take several factors into
consideration, including the possibility of multi-organ
and major vascular resection and the need for adjunct
procedures to minimize complications. We fully advo-
cate thorough preoperative planning and full utilization
of institutional resources and consulting services on an
individual patient basis.
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